Search for dissertations about: "CD40"

Showing result 1 - 5 of 86 swedish dissertations containing the word CD40.

  1. 1. The CD40 Receptor - Target,Tool and Technology

    Author : Peter Ellmark; Institutionen för Immunteknologi; []
    Keywords : MEDICIN OCH HÄLSOVETENSKAP; MEDICAL AND HEALTH SCIENCES; MEDICIN OCH HÄLSOVETENSKAP; MEDICAL AND HEALTH SCIENCES; Immunology; serology; transplantation; Immunologi; serologi; SPIRE; mammalian; library; cDNA; selection; receptor revision; phage display; scFv; human; CD40; antibodies;

    Abstract : CD40 is a cell surface receptor of pivotal importance that is expressed on several of the cells in the immune system. It is critical for many important events, such as T cell dependent B cell activation, isotype switching, somatic mutation and generation of B cell memory. READ MORE

  2. 2. Intratumoral CD40 stimulating therapy in patients with advanced cancer

    Author : Sandra Irenaeus; Gustav Ullenhag; Angelica S. Loskog; Poulam Patel; Uppsala universitet; []
    Keywords : MEDICAL AND HEALTH SCIENCES; MEDICIN OCH HÄLSOVETENSKAP; MEDICIN OCH HÄLSOVETENSKAP; MEDICAL AND HEALTH SCIENCES; CD40; CD40L; immunotherapy; early clinical studies; advanced cancer; intratumoral administration; Medicinsk vetenskap; Medical Science; Oncology; Onkologi;

    Abstract : CD40-CD40L interaction activates DCs to become highly efficient APCs and skews the adaptive immune response towards a Th I phenotype driving cytotoxic T cells, M1 macrophages and natural killer cells. Furthermore, engagement of CD40L to CD40 positive cancer cells can have direct anti-proliferative effects, induce apoptosis and increase expression of MHC and other co-stimulatory molecules, thereby enhancing cancer cell recognition. READ MORE

  3. 3. Tissue Factor and CD40 Ligand : Markers for the Interplay of Coagulation and Inflammation in the Acute Coronary Syndrome

    Author : Anders Mälarstig; Agneta Siegbahn; Lars Wallentin; Taavo Tenno; Fiona Green; Uppsala universitet; []
    Keywords : Molecular medicine; tissue factor; CD40 ligand; gene expression; single nucleotide polymorphism; acute coronary syndrome; myocardial infarction; coagulation; inflammation; Molekylärmedicin;

    Abstract : BACKGROUND: Tissue factor (TF) is a 47 kDa transmembrane glycoprotein known as the main initiator of blood coagulation. CD40 ligand is another membrane molecule, which ligates to cell types associated with atherosclerotic plaques thereby mediating intraplaque inflammation and weakening of the fibrous cap. READ MORE

  4. 4. Immunomodulatory Therapy of Solid Tumors : With a Focus on Monoclonal Antibodies

    Author : Linda Sandin; Thomas Tötterman; Mangsbo Sara; Fredrik Eriksson; Loskog Angelica; Ola Winqvist; Uppsala universitet; []
    Keywords : MEDICAL AND HEALTH SCIENCES; MEDICIN OCH HÄLSOVETENSKAP; MEDICIN OCH HÄLSOVETENSKAP; MEDICAL AND HEALTH SCIENCES; in situ checkpoint blockade; antibody-mediated tumor immunotherapy; CTLA-4; CD40; monoclonal antibodies; experimental animal model; Fc gamma receptor; Medical Science; Medicinsk vetenskap;

    Abstract : Cancer, historically considered a genetic disease, is currently acknowledged to affect the whole body. Our immune system is one key player that can elicit a response against malignant cells but can also promote tumorigenesis. Tumors avoid immune recognition by creating a suppressive microenvironment and inducing tolerance. READ MORE

  5. 5. Diffuse large B-cell lymphoma - tumour characteristics on RNA and protein level associated with prognosis

    Author : Johan Linderoth; Bröstcancer-genetik; []
    Keywords : MEDICIN OCH HÄLSOVETENSKAP; MEDICAL AND HEALTH SCIENCES; MEDICIN OCH HÄLSOVETENSKAP; MEDICAL AND HEALTH SCIENCES; cancerology; Cytologi; Cytology; oncology; prognosis; Diffuse large B-cell lymphoma; CD40; gene expression profiling; tumour microenvionment; Medicin människa och djur ; Medicine human and vertebrates ; onkologi; cancer;

    Abstract : Diffuse large B-cell lymphoma (DLBCL) is the most frequent lymphoma subtype. In Sweden 450 new cases are diagnosed annually. With modern anthracycline-containing chemotherapy DLBCL is potentially curable, with an estimated overall cure rate of approximately 50% for patients with advanced stage disease. READ MORE